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Introduction
A COMPLEX AND HETEROGENEOUS set of genetic alterations is involved in the etiology of breast cancer.
1,2 It is believed that breast cancer, like most other can- cers, has its origin in one cell which through a number of different events becomes malignant. Later additional events lead to the development of different clones with different characteristics. Few genes have been found mutated in breast tumors but large numbers of chromosome arms with so far unidentified genes are affected. These aberrations include Ž . both DNA amplifications and deletions Table 1 . The detected genetic abnormalities in breast tumors Ž are amplification of oncogenes MYC, ERBB2 and . CCND1 , mutation of the TSGs TP53 and CDH1 and Ž . loss of heterozygosity LOH at chromosomes 1, 3p, 6q, 7q, 8p, 9p, 10q, 11, 13q, 16q, 17, 18q, 22q and X. The LOH may correspond to losses or inactivation of TSGs. Several genetic defects have been detected in premalignant breast tissues, suggesting that TSGs might have a role in their pathogenesis. The sequential steps of molecular lesions during breast tumor progression are poorly understood.
Detection of chromosome abnormalities in breast tumors is based on several methods, such as; flow Ž cytometry, cytogenetic studies, FISH, LOH loss of . Ž heterozygosity , CGH comparative genome hy -. bridization . These methods have both advantages and disadvantages. Frequently used markers in LOH studies can give problems in distinguishing between deletions and amplifications. This is especially difficult if the method is based on PCR, but PCR has other advantages, such as utilization of a small sample, and a huge number of highly polymorphic markers tightly distributed over the genome, allowing dense mapping. The CGH and some other methods allow the genome to be screened in a single experiment with respect to losses and gains of genetic material in the tumors, but the resolution power is less than by using molecular markers with well defined locations.
DNA amplification in breast tumors
Several chromosome regions have been documented to carry a gene amplification in breast tumors. These are chromosome 1q, where no strong gene candidate In general only a subset of invasive breast cancer shows amplification at these regions, ranging from 15 to 20%. Nonetheless, elevated expression of CCND1 and HER2 is detected in primary breast carcinoma, when examined immunohistochemically, in a larger proportion of cases. 58 ᎐ 62 The myc oncoprotein is a transcriptional regulator and its expression is strongly associated with cell proliferation and cell differentiation. The CCND1 gene encodes the cyclinD1, an important regulatory molecule of the cell cycle. The Her2 protein is a transmembrane receptor with homology to the epidermal growth factor receptor and contains intrinsic tyrosine kinase activity. Although the biochemical role of these oncoproteins is fairly well characterized, their exact role in breast cancer is poorly defined.
Mutated genes in breast tumors

Tp53
The TP53 gene encodes a transcription factor, p53, that binds as a tetramer to a specific DNA sequence.
The spectrum of TP53 mutations detected in breast tumors with respect to epidemiology has recently been reviewed. 63 This TSG is the most frequently mutated gene in human tumors; approximately 50% of tumors have a mutation in this gene. In breast cancer this frequency is slightly lower; 15᎐34% of tumors have a mutation in the TP53 gene in most ethnic groups, but a higher proportion in certain regions of Japan, or 56᎐71%. 63 The majority of TP53 mutations are missense, in contrast to mutations in several other TSGs, where the majority of mutations result in a truncated protein. Some of the TP53 mutations are dominant negative. The p53 protein is important in the G1 checkpoint of the cell cycle and one described pathway involves the cyclin-dependent Ž .
64 ᎐ 67 kinase inhibitor CKI p21. Upon DNA damage or other stress environment in the cell, p53 accumulates, transactivates the gene encoding the p21 inhibitory protein, and the cell halts in G1 phase of the cell cycle. P53 can even induce apoptosis, and one known pathway is by transcriptional activation of the gene encoding Bax1, an inducer of apoptosis. 68 Interaction of p53 with proteins important for DNA repair has been reported, but functional evidence for a role in DNA repair is still lacking. A feasible model is that p53 is important for blocking the cell from entering the S-phase of the cell cycle upon cell damage, and induces apoptosis if the damage is over-whelming. By failure of p53 normal function due to mutation there is a risk of accumulation of genomic instability and mutations in additional genes. Germline mutations are found in family members of the Li᎐Fraumeni syndrome, and individuals within these families have inherited elevated risk of several cancer types, including breast cancer.
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E-cadherin and lobular breast carcinoma
The E-cadherin gene, CDH1, has been found mutated in a large portion of lobular breast tumors. 70 ᎐ 72 The gene is located on chromosome 16q22.1, a region frequently deleted in breast tumors. The CDH1 behaves like a typical TSG in lobular breast cancer, with one copy of the gene deleted, while the other copy is mutated. No mutations have been detected in the CDH1 gene in tumors in the breast of the ductal histological type. This is the clearest evidence of molecular difference in the two histological types of breast cancer although TP53 mutations are predominantly in tumors of the ductal histological type and other differences are also detected at chromosome Ž . level see later . Reduced expression of E-cadherin has been found in both lobular and ductal breast cancer. 73, 74 Deletions of chromosome 16q22.1 are frequent in ductal carcinoma and this is the highest documented loss of a chromosome region in sporadic breast cancer. 38 It seems that the CDH1 gene does not behave like a typical TSG in ductal breast cancer with respect to the Knudson's two-hit model. 75 Two Ž . explanations of this difference are possible: 1 either a gene other than CDH1 is the target of the 16q22.1 deletions in ductal compared to lobular carcinoma of Ž . the breast; or 2 the progression of ductal carcinoma is more sensitive to loss of one copy of the CDH1 gene, and corresponding reduction of expression, than lobular breast cancer, where both copies need to be knocked out for further progression to malignant invasive growth.
The The majority of the work on variant mRNA has concentrated on their expression in malignant tissues, but it has become apparent that many of them also exist in normal tissues. 79, 80 Several reports are consistent with the involvement of variant ERs in the establishment of certain pathological phenotypes of the breast and it has been suggested that some of the variant ERs have a role in breast tumorigenesis. 81᎐ 83 Still, the physiological and pathological function of variant ER proteins remains unclear. Although it has been suggested that ER mutants may contribute to hormone resistance, direct evidence of an association of ER mutants in breast carcinomas with hormone resistance does not exist. 82, 83 The studies of germ-line mutations of the ESR gene do not support the hypothesis that ER alterations are a major factor in breast cancer risk. 84 The fundamental question if ER mRNA variants have physiological or pathological significance remains conclusively unanswered. Although point mutations in ER can have profound effects on protein function in model systems, their relevance to breast cancer appears to be slight, in terms of risk of development and phenotype of established tumors.
The PTEN gene
The PTEN gene encodes a protein tyrosine phosphatase with homology to tensin. Somatic mutations in the PTEN gene are rare in breast tumors. 85, 86 Germ-line mutations in the PTEN gene are responsi-Ž . 87 ble for Cowden disease CD . Germ-line mutations in the PTEN gene predispose to breast cancer in association with CD.
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BRCA1 and BRCA2 genes
Mutations in the BRCA1 and BRCA2 genes are rare at somatic level but germ-line mutations in these genes predispose to breast cancer.
88 ᎐ 91 An elevation of deletions and amplifications at several chromosome arms in tumors of BRCA1 and BRCA2 carriers compared to tumors from individuals without this mutation have been reported. 92 ᎐ 95 A genome-wide search for the chromosome changes in tumors of BRCA1 and BRCA2 carriers by CGH demonstrated a higher frequency of aberrations at several chromosome arms compared to sporadic tumors. 93 These results suggested a specific tumor progression path- way in patients predisposed to breast cancer due to BRCA1 or BRCA2 mutation. The majority of the regions have previously been implicated in sporadic breast cancer, but in most cases at lower frequency Ž . Figure 1 .
Somatic loss of the wild-type chromosome in tumors of BRCA1 and BRCA2 mutation carriers suggest that both alleles of the corresponding gene are inactivated in cancer, a pattern expected of a TSG.
96 ᎐ 98 Accordingly a high frequency of loss at Ž . chromosome 17q where the BRCA1 gene is located is found in tumors of individuals carrying a BRCA1 germ-line mutation, and a high frequency of loss at Ž . chromosome 13q where the BRCA2 gene is located is found in tumors of individuals carrying a BRCA2 germ-line mutation. Earlier findings based on the loss of wild-type chromosome 13q suggested a strong selection of tumor cells with both alleles of the BRCA2 gene being mutated. 97, 98 It has been shown that the loss at 13q involves the BRCA2 gene in the majority of tumors.
95 So far it is not clear if loss of the wild-type chromosome carrying the BRCA1 or BRCA2 genes, respectively, is prerequisite to enhanced risk of further chromosome alterations.
The 3p chromosome region showing elevation of 3p LOH in BRCA2 tumors involves the FHIT gene at 3p21.1-p14.2. 94, 95 Several reports have described abnormalities in the FHIT gene in breast carcinomas.
99 ᎐ 101 Furthermore, the FHIT gene has been shown to suppress tumorigenicity of cancer cells. 102 The FHIT gene encompasses the carcinogen sensitive common fragile site, FRA3B. 103 Crook et al has documented an elevated proportion of TP53 mutations in tumors from BRCA1 carriers compared to sporadic tumors. 104 These results suggest that loss of cell cycle checkpoint due to somatic TP53 mutation may increase the rate of BRCA1 tumorigenesis. Furthermore, the region at chromosome 17p harboring the TP53 gene shows a significant elevation of LOH in BRCA2 tumors in comparison to sporadic tumors. 105 Knockout mouse experiments have suggested that p53 protein is accumulating in Brca2 defective mice and that a cell cycle checkpoint mechanism is activated due to defective BRCA2 protein and corresponding DNA damage. 106 It has been suggested that accumulation of p53 protein can reduce the malignant behavior of BRCA2 defective tumors due to cell cycle checkpoint activation. 107 Still, no significant elevation of TP53 somatic mutations is detected in tumors from individuals carrying BRCA2 germ line mutation. 105, 108 The growth advantage of BRCA2 defective tumors may be enhanced if only one copy of the TP53 gene is deleted.
The association of both Brca1 and Brca2 proteins with the Rad51 protein establishes a direct link between these proteins and the control of genomic integrity and stability since Rad51 is required for meiotic and mitotic recombination events and the repair of double stranded DNA breaks. 109, 110 Furthermore, fibroblasts from Brca2 knockout mice show defects in DNA repair of double stranded breaks. 107 Defects in chromatid exchange during mitotic recombination result in numerous spontaneous chromosomal abnormalities in fibroblasts from Brca2 knockout mice. 111 The increased number of somatic alterations at chromosome level may reflect the inability of mutated Brca1 or Brca2 proteins to participate in the Rad51 mediated repair. A putative model of LOH selection might be that due to improper fidelity in mitotic recombination and corresponding DNA repair, the tumors with BRCA1 or BRCA2 mutation follow a more aggressive pathway of chromosome damage than tumors without this mutation. Whether loss of additional genes is involved in the tumor progression of BRCA1 and BRCA2 carriers compared to sporadic tumors remains unsolved.
The architecture of the LOH is different in BRCA2 and sporadic tumors at some chromosome regions, as the BRCA2 tumors involve larger regions. 94, 95 In tumors showing loss at a given chromosome arm, specific regions can be preferably affected in BRCA1 or BRCA2 tumors in comparison to sporadic tumors. These findings may pinpoint candidate loci for the search of genes that when inactivated promote tumor progression in individuals predisposed to breast cancer due to a germ-line BRCA1 or BRCA2 mutation.
The large number of abnormal chromosomes observed in tumor cells in BRCA1 and BRCA2 individuals supports the belief that their protein product is involved in maintaining appropriate chromosome segregation andror chromosomal repair. The high number of genetic defects that are detected in BRCA1 and BRCA2 carriers indicates that germ-line mutation of these genes results in an accelerated accumulation of secondary somatic genetic changes in the tumors. This acceleration could explain the aggressive phenotype of tumor growth in tumors from BRCA2 carriers, as breast cancers associated with the BRCA2 mutation are high grade tumors with a rapid proliferation rate. 112 The chromosome defects in BRCA1 and BRCA2 tumors are likely to be helpful in the understanding of the somatic genetic progression pathways that contribute to the development of malignancy in genetically predisposed individuals.
Premalignant breast tissue and tumor progression
The development of breast cancer involves many types of genes that need to be activated or inactivated in order to promote malignancy. This is a complex process, where for most tumor types the steps involved are not known. For breast cancer the sequential steps in gene alterations with respect to tumor progression are not clear, far less understood than what is currently the best example of tumor progression, colorectal carcinoma. Putative precursor stages to invasive tumor growth; such as usual ductal hyperplasia, atypical hyperplasia and cancer in situ of the breast have been studied. The detected LOH in hyperplastic disease suggests that hyperplasias are really benign neoplasms and inactivation of TSGs participates in their development. 113 In
Gene amplifications appear to be a late event in tumor progression, being mainly found in tumor cells that have acquired genomic instability and tolerate its presence.
2 None of the oncogenes located at amplified chromosomal region are amplified in benign breast disease. 58, 118, 119 In ductal hyperplasia with or without atypia, oncogene amplification is detected at only low levels for genes located on 11q13. 120 It may be concluded that oncogene amplification is not an early event in the multistep carcinogenesis of breast cancer but emerges in ductal carcinoma in situ. 2 The percentage of oncogene amplification varies with the histological subtype of ductal carcinoma in situ, for example, HER2 amplification is lower in the cribriform type compared to the comedo type. 121 The overall rate of HER2 amplification in ductal carcinoma in situ is decreasing towards the development of invasive ductal carcinoma and is absent in lobular carcinoma in situ and very rare in invasive lobular carcinoma. 122 This is different for other oncogenes; for example, CCND1 amplification is similar in ductal carcinoma in situ and in invasive ductal carcinoma. 120 All oncogenes show low amplification rate in invasive lobular carcinoma. 121 These findings are consistent with the biological and histological difference between lobular and ductal carcinoma in situ. It can be concluded that the oncogene amplification seems to be specific for a certain histological subtype; the oncogene mediated proliferation is predominantly at the intermediate state of breast cancer development and is not of obvious importance in the progression to metastatic disease. 2 Ž In a study of benign breast disease fibroadenomas, . benign phyllode tumors, fibrocytic diseases no LOH was detected at chromosome loci 1p, 3p, 7q, 11p, 17p, 17q and 18q. 119 O'Connell et al reported that in hyperplasias from noncancerous breast, LOH at any given locus is rare although 37% of usual ductal hyperplasia and 42% of atypical ductal hyperplasias show losses, suggesting that the development of hyperplasias can involve many different TSGs. 123 Apocrine cysts and papillomas of the breast are negative for LOH, while hyperplasias of usual type exhibit LOH at chromosome regions 16q, 17p and 17q and the atypical ductal hyperplasia show LOH at chromosomes 16q and 17p. 124, 125 In ductal carcinoma in situ from non-cancerous breasts, LOH was common, including LOH at loci on chromosome 16q, 17p and 17q, suggesting that inactivation of TSGs in these regions may be important in the development of non-invasive breast cancer. 123 Additional LOH was detected in in situ growth in cancerous breasts, for instance on chromosome 2p, 11p and 17q, suggesting that genetic alterations in these regions may be important in the progression to invasive disease. 123 Certain changes appear to develop early, e.g. loss at chromosome 3p, while other changes, like loss at chromosome 11p and 15, appear late in tumor progression. 126 ᎐ 128 In a subset of tumors, loss of 11p was only observed in the invasive tumor and not the corresponding cancer in situ. 125 High incidence of loss on chromosome 15 was detected in metastasis from the breast, suggesting that a gene on chromosome 15 contributes to the pathogenesis of metastatic breast carcinoma. 128 In general, these findings support the idea that the putative precursors and the cancers are related. Some of the changes found in the hyperplastic, premalignant and malignant breast epithelium, like LOH of 3p, also exist in apparently normal cells adjacent to the tumor. 126 A model to explain this is that the first mutation may occur early in breast cancer progression before clonal expansion occurs, suggesting that the molecular heterogeneity of the invasive tumor may occur at the earliest detectable stages of progression.
RER and breast cancer
Ž . Replication errors RER are key features of heredi-Ž . tary non-polyposis colorectal cancer HNPCC and an indicator of defects in the DNA mismatch repair genes. 129 Screening of sporadic colorectal tumors has revealed that 12᎐28% of cases are of the RER q phenotype. 130, 131 It has been reported that RER q is also present in significant sub-sets of common, nonhereditary forms of cancer of the gastrointestinal tract, endometrium and lung and, at a lower frequency, in ovarian, brain and soft-tissue tumors. 132 ᎐ 136 Breast cancer is rarely associated with the HNPCC phenotype. 137 132 In independent studies RER q Ž . Ž . has been reported in 5% 5r93 and 8% 8r100 of primary breast tumors, respectively. 140, 141 Our results Ž . indicate that RER exists in 8r419 1.9% of primary ductal breast cancer cases at one or more chromosomal loci and that no RER was observed in 40 cases of primary lobular breast cancer. 142 Bergthorsson et al suggested three explanations for the appearance of replication error in sporadic breast cancer: 143 First, the instability observed is not caused by mismatch repair gene defects, but rather reflects the ability of this repair system to work in the environment provided by the tumor cell. Secondly, sporadic RER q tumors could be caused by mild mutations, and perhaps in different genes. Finally, sporadic breast tumors may have a defective mismatch repair system but need an additional environmental or genetic co-factor to result in a strong RER q phenotype. The breast cancer cases with RER do not seem to be part of a HNPCC syndrome since a family history of colorectal cancer growth is not detected in relatives. 142 It can be concluded that RER is a rare somatic event during human breast carcinogenesis and may be associated with progression of breast carcinomas.
Mutations and prognosis
A large number of molecular markers have been suggested to give prognostic information in breast cancer. Overexpression andror amplification of the HER2 oncogene generally correlates with poor prognosis for breast cancer patients. 59, 61, 144, 145 The HER2 overexpression correlates with tumor grade, size, relapse rate, and lymph node and distant metastases. 59 In addition to prognosis and prediction of response to chemotherapeutic drugs, the HER2 oncogene may also have an important role in breast cancer therapy. 62 Baselga et al used weekly intravenous injections of humanized monoclonal antibody against the Her2 protein in patients with overexpressing metastatic breast cancer in phase II clinical trial. Their results were not dramatic, but 11.6% overall response rate in this usually refractory subset of patients was documented. 62 Other molecular markers have been studied less with respect to prognosis and therapy. It has been suggested that p53 mutation is an important prognostic indicator of short-term survival for breast cancer patients. 146, 147 The TP53 gene mutations could be an important factor to identify node-negative patients who have a poor prognosis in the absence of adjuvant therapy. 147 Furthermore, LOH at chromosomes 1p, 3p, 6q, 11q and 13q have been shown to be of independent prognostic value.
7,8,10,12,27,31,35,148 It is not clear if this prognostic association is due to inactivation of specific TSGs or reflects the general chromosome instability in the tumor. E-cadherin expression has been shown to be associated with decreased overall survival of breast cancer patients. 
